EFFEXOR

Compare EFFEXOR  to:
Compare
Compare

Generic Name for EFFEXOR

Venlafaxine (as HCl) 25mg, 37.5mg, 50mg, 75mg, 100mg; scored tabs.

Legal Classification:

Rx

Pharmacological Class for EFFEXOR

Serotonin and norepinephrine reuptake inhibitor.

Manufacturer of EFFEXOR

Pfizer Labs

Indications for EFFEXOR

Depression.

Adult dose for EFFEXOR

Take with food. ≥18yrs: Initially 75mg/day in 2–3 divided doses; may increase at 4-day intervals in 75mg/day increments to 150mg/day; max 375mg/day, in 3 divided doses. Hepatic impairment: reduce by at least 50%. Mild-to-moderate renal impairment: reduce by at least 25%; hemodialysis: reduce by 50% (hold dose until end of dialysis treatment). Withdraw gradually (over 2 weeks).

Children's dosing for EFFEXOR

<18 yrs: not recommended.

Also:

Contraindications for EFFEXOR

MAOIs (see Interactions).

Warnings/Precautions for EFFEXOR

Monitor blood pressure; reduce dose or discontinue if elevated BP persists. Heart disease (eg, recent MI, heart failure). Hypercholesterolemia (consider monitoring in long-term use). Renal or hepatic dysfunction. Increased intraocular pressure. Diseases that affect metabolism or hemodynamic response (eg, hyperthyroidism). Mania. Seizure disorders. Reevaluate periodically. Suicidal ideation. Write ℞ for smallest practical amount. Elderly. Labor & delivery. Pregnancy (Cat.C) (avoid 3rd trimester; see literature for effects on neonate). Nursing mothers: not recommended.

Interactions for EFFEXOR

Allow at least 14 days after MAOI discontinuance before starting venlafaxine; allow at least 7 days after venlafaxine discontinuance before starting an MAOI. Avoid alcohol. Concomitant weight loss agents (eg, phentermine), serotonin precursors (tryptophan supplements): not recommended. Monitor for serotonin syndrome with SSRIs, SNRIs, triptans (esp. during initiation and dose increases). Caution with other CNS drugs, cimetidine, haloperidol, diuretics, drugs that inhibit both CYP2D6 and CYP3A4.

Adverse Reactions for EFFEXOR

GI upset, dizziness, somnolence, insomnia, sexual dysfunction, sweating, dry mouth, nervousness, asthenia, tremor, vasodilation, hypertension, abnormal dreams or vision, yawn, paresthesia, agitation, ecchymosis, anorexia, weight changes; hyponatremia/SIADH (esp in elderly).

How is EFFEXOR supplied?

Caps, tabs—100

Related Disease:

Depression

Related Resources

FDA warns of aseptic meningitis risk with Lamictal

August 13, 2010

The FDA has informed healthcare professionals and patients that Lamictal (lamotrigine, from GlaxoSmithKline) can cause aseptic meningitis.

Oleptro available for major depressive disorder

August 10, 2010

Labopharm and Angelini announced the launch of Oleptro (trazodone HCl extended-release tablets) for the treatment of major depressive disorder (MDD) in adults.

Phase 3 study of TC-5214 for major depressive disorder (MDD)

June 23, 2010

AstraZeneca and Targacept announced the enrollment of the first patient in their Phase 3 development program for TC-5214 as an adjunct treatment for major depressive disorder (MDD) in patients with an inadequate response to first-line therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI).

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

NDA submitted for vilazodone for major depressive disorder (MDD)

March 23, 2010

Clinical Data Inc. announced that a New Drug Application (NDA) has been submitted to the FDA seeking approval of vilazodone for the treatment of major depressive disorder (MDD).

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions